Invivyd (IVVD) Equity Average (2021 - 2025)
Invivyd posted quarterly Equity Average of $167.3 million for Q4 2025, up 122.04% year-on-year from $75.4 million in Q4 2024, and up 146.29% on a QoQ basis from $67.9 million in Q3 2025.
Invivyd (IVVD) has 5 years of Equity Average data on file, last reported at $167.3 million in Q4 2025.
- For the quarter ending Q4 2025, Equity Average rose 122.04% year-over-year to $167.3 million; the trailing twelve-month figure through Dec 2025 stood at $167.3 million (up 122.04% YoY), and the FY2025 full-year result was $154.5 million, up 26.15% from the prior year.
- Equity Average for Q4 2025 stood at $167.3 million, up from $67.9 million in the prior quarter.
- Across five years, Equity Average topped out at $595.6 million in Q4 2021 and bottomed at -$124.0 million in Q2 2021.
- The 5-year median for Equity Average is $195.0 million (2023), against an average of $216.6 million.
- The widest annual swing landed in 2022, when Equity Average surged 703.41%; it then slumped 69.63% in 2025.
- A 5-year view of Equity Average shows it stood at $595.6 million in 2021, then tumbled by 38.43% to $366.7 million in 2022, then plunged by 42.19% to $212.0 million in 2023, then plunged by 64.45% to $75.4 million in 2024, then surged by 122.04% to $167.3 million in 2025.
- The last three Equity Average figures came in at $167.3 million (Q4 2025), $67.9 million (Q3 2025), and $48.5 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Invivyd | 208.38 Mn | -18.31 Mn | - | 167.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 167.30 Mn |
| Sep 30, 2025 | 67.93 Mn |
| Jun 30, 2025 | 48.47 Mn |
| Mar 31, 2025 | 60.84 Mn |
| Dec 31, 2024 | 75.35 Mn |
| Sep 30, 2024 | 111.90 Mn |
| Jun 30, 2024 | 159.57 Mn |
| Mar 31, 2024 | 177.98 Mn |
| Dec 31, 2023 | 211.98 Mn |
| Sep 30, 2023 | 264.03 Mn |
| Jun 30, 2023 | 304.16 Mn |
| Mar 31, 2023 | 341.36 Mn |
| Dec 31, 2022 | 366.71 Mn |
| Sep 30, 2022 | 396.14 Mn |
| Jun 30, 2022 | 437.12 Mn |
| Mar 31, 2022 | 508.71 Mn |
| Dec 31, 2021 | 595.62 Mn |
| Sep 30, 2021 | 244.29 Mn |
| Jun 30, 2021 | -123.99 Mn |
| Mar 31, 2021 | -84.31 Mn |